Company Overview
Autonomix Medical, Inc. operates as a development stage medical device company dedicated to advancing technologies designed for sensing and treating disorders associated with the peripheral nervous system. The company utilizes a technology platform that incorporates a catheter-based microchip-enabled sensing array to detect and differentiate specific medical conditions within this specialized domain. This entity functions within the Healthcare sector and specifically targets the Medical Devices industry, positioning itself as a niche player focused on innovative therapeutic solutions rather than established mass-market products. The company currently maintains a market capitalization of $4.57M and employs a workforce of 8 individuals, indicating a very early-stage operational scale. These valuation and headcount figures suggest that Autonomix Medical is in a pre-revenue or initial commercialization phase where capital allocation is heavily weighted toward research and development rather than scaling production or generating significant free cash flow.
Financial Health
The financial statements for Autonomix Medical, Inc. reveal a net income (TTM) of $-17,240,000 and an EBITDA of $-17,492,000, while annual revenue is listed as N/A for the trailing twelve months. The absence of reported revenue combined with substantial net losses indicates that the company has not yet achieved commercial profitability or that its revenue is not yet material enough to be reported under current thresholds, resulting in a cost structure where expenses vastly outpace any generated income. The company reports a free cash flow of $-5,933,875, which signifies that operating activities and investing activities are consuming cash reserves rather than generating liquidity, thereby limiting financial flexibility for immediate expansion or debt repayment. Three margin metrics—gross margin, operating margin, and profit margin—are all recorded at 0.0%, reflecting either a lack of recognized revenue or a state where costs exceed all potential earnings before interest and taxes. On the balance sheet, the company holds $9.93M in cash while debt is listed as N/A, and the debt-to-equity ratio is also N/A, suggesting the firm is currently un-leveraged and relying on equity financing or cash reserves to fund operations. The current ratio stands at 6.18, which indicates a highly conservative short-term liquidity position where current assets significantly exceed current liabilities, providing a robust buffer against immediate obligations. Return on Equity is reported at -188.7% and return on assets at -99.0%, metrics that reveal the company is currently destroying shareholder value and utilizing assets inefficiently due to the heavy burn rate associated with its development stage status.
Valuation Assessment
Valuation metrics for Autonomix Medical, Inc. show a P/E Ratio (TTM) of N/A and a forward P/E of -0.05, a disparity that implies earnings are currently negative and traditional price-to-earnings multiples cannot be applied to assess historical performance. The price-to-book ratio is 0.53, indicating that the market values the company at approximately half of its book value, which often occurs with development-stage biotech or medical device firms where tangible assets do not fully capture the potential value of the intellectual property pipeline. Since revenue is N/A, the price-to-sales ratio is also N/A, and the EV/EBITDA is 0.31, suggesting that enterprise value is being calculated based on a very low multiple of earnings before interest, taxes, depreciation, and amortization, likely reflecting the high risk and lack of current profitability. The stock has traded between a 52-week high of $2.82 and a 52-week low of $0.34, and given the forward P/E of -0.05 and the absence of positive earnings, the current price sits in a range heavily influenced by speculative interest rather than fundamental earnings support. The beta value is -2.79, a figure that is highly anomalous for equities and suggests extreme price volatility or a data anomaly where the stock moves inversely to the broader market or exhibits magnified swings relative to the market index.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of whether earnings are growing faster or slower than revenue, as the company has not yet established a consistent growth trajectory or reported positive earnings. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning Autonomix Medical, Inc. reinvests all available capital and any potential earnings back into the business to fund its development activities rather than distributing income to shareholders. This lack of dividend payments combined with negative cash flow and N/A growth rates underscores a growth profile that relies entirely on external capital markets to sustain operations and advance its peripheral nervous system technologies. The overall growth and income profile is characterized by a complete absence of current income generation and undefined growth rates, reflecting the typical characteristics of a development stage company that prioritizes technological advancement over shareholder returns or financial stability.